NCT07020533 - A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 8, 2026

Primary Completion Date

June 1, 2027

Study Completion Date

June 1, 2027

Conditions

Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic LeukemiaChronic Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveHematopoietic and Lymphatic System NeoplasmHodgkin LymphomaLymphoblastic LymphomaMyelodysplastic SyndromeMyelofibrosisMyeloproliferative NeoplasmNon-Hodgkin Lymphoma

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

OTHER

Electronic Health Record Review

Ancillary studies

PROCEDURE

Haploidentical Hematopoietic Cell Transplantation

Undergo HCT

DRUG

Letermovir

Given IV or PO

BIOLOGICAL

Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

Given IM

PROCEDURE

Myeloablative Conditioning

Receive myeloablative conditioning

PROCEDURE

Pheresis

Undergo apheresis

BIOLOGICAL

Recombinant Granulocyte Colony-Stimulating Factor

Given G-CSF

Trial Locations (3)

30342

Northside Hospital, Atlanta

91010

City of Hope Medical Center, Duarte

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER